Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA)

Area of Science:

• Hepatology
• Cancer Biology
• Molecular Therapy

Background:

• Hepatocellular carcinoma (HCC) exhibits poor clinical outcomes due to tumor recurrence and resistance to conventional therapies.
• Cancer stem cells (CSCs) are a subpopulation of cells responsible for tumor initiation, progression, metastasis, and therapeutic resistance in HCC.
• Recent advancements have identified hepatic CSC surface markers, enabling their isolation and study.

Purpose of the Study:

• To outline the characteristics of CSCs in HCC.
• To explore novel therapeutic strategies targeting hepatic CSCs.
• To address the challenge of HCC resistance to traditional treatments.

Main Methods:

• Identification and characterization of hepatic CSC surface markers (e.g., EpCAM, CD133, CD90, CD44).
• Investigation of the role of CSCs in HCC development, invasiveness, self-renewal, metastasis, and drug resistance.
• Exploration of small interfering RNA (siRNA) as a targeted therapeutic approach against hepatic CSCs.

Main Results:

• Hepatic CSCs significantly influence HCC progression and resistance mechanisms.
• Specific surface markers facilitate the identification and isolation of hepatic CSCs.
• siRNA-based strategies show potential for disrupting CSC behavior and overcoming treatment resistance.

Conclusions:

• Targeting hepatic CSCs is crucial for preventing HCC recurrence and improving treatment efficacy.
• siRNA-mediated targeting of hepatic CSCs represents a promising therapeutic avenue.
• Further research into CSC-specific therapies is essential for advancing HCC treatment.